Evidence map›Paper›PMID 37100830›Full record

Trial reportScientific reports2023

Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients.

Jens Peter Klussmann, Maria Grosheva, Peter Meiser, Clara Lehmann, Eszter Nagy, Valéria Szijártó, Gábor Nagy, Robert Konrat, Michael Flegel, Frank Holzer and 17 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 4 institutions in 2 countries.

Jens Peter KlussmannCenter for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Maria GroshevaMedical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Peter MeiserURSAPHARM Arzneimittel GmbH, Industriestraße 35, 66129, Saarbruecken, Germany.
Clara LehmannCenter for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Eszter NagyCEBINA GmbH, Karl-Farkas-Gasse 22, 1030, Vienna, Austria.
Valéria SzijártóCEBINA GmbH, Karl-Farkas-Gasse 22, 1030, Vienna, Austria.
Gábor NagyCEBINA GmbH, Karl-Farkas-Gasse 22, 1030, Vienna, Austria.
Robert KonratDepartment of Structural and Computational Biology, Max F. Perutz Laboratories, University of Vienna, Dr.-Bohr-Gasse 9, 1030, Vienna, Austria.
Michael FlegelURSAPHARM Arzneimittel GmbH, Industriestraße 35, 66129, Saarbruecken, Germany.
Frank HolzerURSAPHARM Arzneimittel GmbH, Industriestraße 35, 66129, Saarbruecken, Germany.
Dorothea GroßURSAPHARM Arzneimittel GmbH, Industriestraße 35, 66129, Saarbruecken, Germany.
Charlotte SteinmetzURSAPHARM Arzneimittel GmbH, Industriestraße 35, 66129, Saarbruecken, Germany.
Barbara SchererURSAPHARM Arzneimittel GmbH, Industriestraße 35, 66129, Saarbruecken, Germany.
Henning GruellLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Maike SchlotzLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Florian KleinGerman Center for Infection Research (DZIF) Location Bonn-Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Paula Aguiar de AragãoMedical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Henning MorrMedical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Helal Al SalehMedical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Andreas BilsteinUrsatec GmbH, Marpinger Weg 4, 66636, Tholey, Germany.
Belisa RussoClinCompetence Cologne GmbH, Theodor-Heuss-Ring 14, 50668, Cologne, Germany.
Susanne Müller-ScholtzClinCompetence Cologne GmbH, Theodor-Heuss-Ring 14, 50668, Cologne, Germany.
Cengizhan AcikelClinCompetence Cologne GmbH, Theodor-Heuss-Ring 14, 50668, Cologne, Germany.
Hacer SahinClinCompetence Cologne GmbH, Theodor-Heuss-Ring 14, 50668, Cologne, Germany.
Nina WerkhäuserClinCompetence Cologne GmbH, Theodor-Heuss-Ring 14, 50668, Cologne, Germany.
Silke AllekotteClinCompetence Cologne GmbH, Theodor-Heuss-Ring 14, 50668, Cologne, Germany.
Ralph MösgesClinCompetence Cologne GmbH, Theodor-Heuss-Ring 14, 50668, Cologne, Germany. ralph@moesges.de.
University of Cologne · DEURSAPHARM (Germany) · DEUniversity Hospital Cologne · DEMax Perutz Labs · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the changing epidemiology of COVID-19 and its impact on our daily lives, there is still an unmet need of COVID-19 therapies treating early infections to prevent progression. The current study was a randomized, parallel, double-blind, placebo-controlled trial. Ninety SARS-CoV-2 positive patients were randomized into 3 groups receiving placebo, 0.02% or 0.1% azelastine nasal spray for 11 days, during which viral loads were assessed by quantitative PCR. Investigators assessed patients' status throughout the trial including safety follow-ups (days 16 and 60). Symptoms were documented in patient diaries. Initial viral loads were log

Indexed as

COVID-19SARS-CoV-2Double-Blind MethodHumansNasal SpraysPhthalazinesTreatment OutcomeViral LoadazelastineNasal SpraysPhthalazines

Identifiers

PMID37100830
PMCPMC10132439
OpenAlexW4367050420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.